Safety study of IMM-H014 in healthy adults
Treatments studied
Part of Digestive system clinical trials.
This trial tests a new drug called IMM-H014 in healthy volunteers to see if it is safe and how the body processes it. It also checks if food changes how the drug works. You may join if you are generally healthy and meet the age and weight requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old
- You weigh at least 50 kg (110 lbs) if male or 45 kg (99 lbs) if female
- Your body mass index (BMI) is between 18 and 28
- You are willing to use effective birth control for 6 months after the study
- You have no major health conditions like heart, liver, kidney, or stomach problems
- You have not taken any prescription or over-the-counter meds, herbs, or supplements in the last 2 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, IMM-H014, for a liver condition called MASH (metabolic dysfunction-associated steatohepatitis). It looks at how well people tolerate the drug and how it works in the body. This might help if you have fat buildup in your liver along with other health issues like high blood pressure, diabetes, or high cholesterol.
This Phase 2 study tests whether SNP-610 (or a placebo) can improve non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. It also checks safety by comparing outcomes between the two groups.
This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.
This early-stage study checks if a new medicine called HEC169584 is safe for people and how it moves through the body. It looks for healthy volunteers to take part.
This is an early-stage safety test of a new investigational drug called HSK56630 in healthy volunteers with no major medical conditions. Researchers will monitor how your body tolerates the drug and what side effects might occur.
This trial tests a potential new medicine (NNC4005-0001) for liver disease in adults who have extra body weight and excess fat in their liver. It aims to see if the medicine can help improve liver health.
Hear when a new Nonalcoholic Steatohepatitis (NASH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.